Jeffrey Aube

This inventor holds 21 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: University of Kansas, Scripps Research Institute, Southern Research Institute. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey Aube. Retrieved from https://idiyas.com/inventor/jeffrey-aube

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 5)

% Patents Active = 61.9

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 33(Granted Patents)

Company Filing History:

Scripps Research Institute

patents

4 out of 205

Southern Research Institute

patents

4. 3 out of 943

The University of New Mexico

patents

5. 3 out of 398

University Of Louisville Research Foundation, Inc.

patents

6. 2 out of 99

Sanford-Burnham Medical Research Institute

patents

7. 2 out of 3,525

University of Michigan

patents

8. 2 out of 602

Wayne State University

patents

9. 1 out of 4,625

California Institute of Technology

patents

10. 1 out of 7

Cleave Biosciences, Inc.

patents

11. 1 out of 89

Uwm Research Foundation, Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2020

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10829453 - Antagonists of the kappa opioid receptor (2020-11-10),

2. 10787439 - Compounds and methods for activating the apoptotic arm of the unfolded protein response (2020-09-29),

3. 10532999 - 6-substituted quinazolinone inhibitors (2020-01-14),

4. 10118896 - Antagonists of the kappa opioid receptor (2018-11-06),

5. 10087168 - 6-substituted quinazolinone inhibitors (2018-10-02),

6. 10059722 - Cephalosporin derivatives and methods of use (2018-08-28),

7. 9732067 - Compounds and methods for activating the apoptotic arm of the unfolded protein response (2017-08-15),

8. 9642835 - Modulators of GTPase and use in relevant treatment (2017-05-09),

9. 9611270 - Inhibitors of CYP17A1 (2017-04-04),

10. 9580393 - 6-substituted quinazolinone inhibitors (2017-02-28),

11. 9540375 - Kappa opioid receptor effectors and uses thereof (2017-01-10),

12. 9499496 - Inhibitors of respiratory syncytial virus (2016-11-22),

13. 9464064 - HCV helicase inhibitors and methods of use thereof (2016-10-11),

14. 9376452 - Rab7 GTPase inhibitors and related methods of treatment (2016-06-28),

15. 9345703 - Kappa opioid receptor effectors and uses thereof (2016-05-24),

Title: Innovations and Contributions of Jeffrey Aube in Pharmaceutical Science

Introduction

Jeffrey Aube is a distinguished inventor based in Lawrence, Kansas, known for his significant contributions to pharmaceutical science. With a portfolio of 21 patents, Aube's innovative work focuses primarily on compounds that address various medical conditions.

Latest Patents

Among his latest patents, Aube has developed non-morphinan-like kappa opioid receptor (KOR) antagonists. This technology targets multiple conditions such as addiction, depression, and anxiety disorders. Additionally, he has worked on compounds for activating the apoptotic arm of the unfolded protein response, aiming to treat severe diseases, including diabetes, Alzheimer's, and cancer.

Career Highlights

Aube has had a prominent career, contributing his expertise to renowned institutions such as the University of Kansas and The Scripps Research Institute. His research has paved the way for advancements in therapeutic modalities that significantly improve patient lives.

Collaborations

Throughout his career, Aube has collaborated with noteworthy professionals, including Jennifer Elizabeth Golden and Kevin Frankowski. These partnerships have fostered an environment of innovation and made a significant impact in their respective fields.

Conclusion

Jeffrey Aube embodies the spirit of innovation in pharmaceutical science with his extensive patent portfolio and impactful research. His commitment to addressing complex medical challenges through inventive solutions continues to inspire the scientific community and improve healthcare outcomes for many individuals.

Profile summary based on public USPTO records.